ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2332

Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib

W. F. C. Rigby1, L. Takiya2, S. P. Wood3, H. Fan2 and T. V. Jones2, 1Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Pfizer Inc, Collegeville, PA, 3Pfizer Inc, Groton, CT

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Diabetes, Infection, Lipids, rheumatoid arthritis, treatment and tofacitnib

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus (DM) in patients (pts) with RA. Nearly 9% of pts enrolled into Phase 3 (P3) studies of tofacitinib in RA also had DM. Both RA and DM are associated with lipid changes and an increased risk of infection. This analysis evaluated selected safety endpoints in pts with and without DM receiving tofacitinib for RA.

Methods: Safety endpoints, including changes in fasting blood glucose (FBG), lipids and risk of all infections (regardless of severity), were evaluated in a post-hoc pooled analysis of five tofacitinib P3 studies in DMARD inadequate responders. Baseline (BL) clinical characteristics and lab data, and follow-up lipid data at Month (Mo) 3, were available for all studies. Follow-up FBG data were available for four studies of tofacitinib with background nonbiologic DMARDs. Categorical changes (defined by the American Diabetes Association [ADA]) in FBG vs BL were compared using shift analyses.

Results: Of 2430 pts who received tofacitinib, 8.7% (211) had DM: 8.9% (108/1216) 5 mg BID; 8.5% (103/1214) 10 mg BID. Additionally, 7.0% (48/681) of pts receiving placebo (PBO) had DM. At BL, 49.1% (tofacitinib 5 mg BID), 46.6% (tofacitinib 10 mg BID), and 50% (PBO) of pts with DM used glucocorticoids.

Mean BL FBG in pts with DM was 138 mg/dL, 129.8 mg/dL and 138.9 mg/dL in the tofacitinib 5 mg BID, 10 mg BID and PBO groups, respectively. Corresponding values at Mo 3 were 126.1 mg/dL, 124.0 mg/dL and 129.5 mg/dL. The shift analysis of FGB data from 82 tofacitinib 5 mg BID pts with DM showed 10 pts moved from lower to higher ADA category at BL at Mo 1 or 3, while 19 pts moved from higher to lower category (53 with no change, see Table). For tofacitinib 10 mg BID pts with DM, numbers moving to higher, lower, or no change in category were 19, 13, and 46, respectively. Corresponding numbers for PBO pts with DM were 9, 9, and 25 (not shown).

Increases in mean low density lipoprotein (LDL) and triglyceride (TG) levels were observed at Mo 3 in pts treated with tofacitinib, as reported previously, although the same pattern was seen in pts with and without DM. During 3 Mo of follow-up 23.1%, 21.4% and 25.0% of pts with DM in the tofacitinib 5 mg BID, 10 mg BID and PBO groups, respectively, had ≥1 infection. Corresponding proportions in pts without DM were 21.0%, 21.8% and 18.6%.

Conclusion: In the P3 studies evaluated, pts with RA and DM showed no increase in mean FBG levels after 3 Mo of tofacitinib therapy; the number of pts with DM whose FBG increased to ≥126 mg/dL was limited and similar to that observed in pts receiving PBO. Mean increases in LDL and TG were numerically similar in pts with and without DM. The proportion of tofacitinib-treated pts who experienced ≥1 infection, regardless of severity, was numerically similar between pts with and without DM.

 

Table. Shift analysis of maximum fasting blood glucose levels from baseline to
Month 1 or Month 3 in patients with rheumatoid arthritis and diabetes mellitus receiving tofacitinib 5 mg or 10 mg twice daily

 

Maximum on-treatment FBG (mg/dL at Month 1 or Month 3)

<100

n (%)

100-125

n (%)

≥126

n (%)

Total

n (%)

 

Tofacitinib
5 mg BID

 

Baseline FBG (mg/dL)

<100
n (%)

15 (63)

5 (21)

4 (17)

24 (100)

100-125
n (%)

7 (41)

9 (53)

1 (6)

17 (100)

≥126
n (%)

2 (5)

10 (24)

29 (71)

41 (100)

Total

n (%)

24 (29)

24 (29)

34 (41)

82 (100)

Tofacitinib
10 mg BID

 

Baseline FBG (mg/dL)

<100
n (%)

8 (10.3)

6 (7.7)

4 (5.1)

18 (23.1)

100-125
n (%)

5 (6.4)

12 (15.4)

9 (11.5)

26 (33.3)

≥126
n (%)

1 (1.3)

7 (9.0)

26 (33.3)

34 (43.6)

Total

n (%)

14 (17.9)

25 (32.1)

39 (50.0)

78 (100.0)

BID, twice daily; FBG, fasting blood glucose

Only patients with valid fasting blood glucose measurements at baseline and an

on-treatment value at Month 1 or Month 3 are included


Disclosure:

W. F. C. Rigby,

Roche Pharmaceuticals,

5;

L. Takiya,

Pfizer Inc.,

1,

Pfizer Inc.,

3;

S. P. Wood,

Pfizer Inc,

1,

Pfizer Inc,

3;

H. Fan,

Pfizer Inc,

1,

Pfizer Inc.,

3;

T. V. Jones,

Pfizer Inc.,

1,

Pfizer Inc,,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-lipid-changes-and-infection-risk-in-diabetic-and-nondiabetic-patients-with-rheumatoid-arthritis-treated-with-tofacitinib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology